Pegcantratinib - Sienna Biopharmaceuticals

Drug Profile

Pegcantratinib - Sienna Biopharmaceuticals

Alternative Names: CT 301/P; CT 327; K-252a-PEG2K; Pegylated K252A; SNA-120

Latest Information Update: 29 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Developer Creabilis SA; Sienna Biopharmaceuticals
  • Class Antipsoriatics; Carbazoles; Indole alkaloids; Skin disorder therapies; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis; Pruritus
  • Discontinued Neuropathic pain

Most Recent Events

  • 27 Aug 2018 Sienna Biopharmaceuticals completes enrolment in a phase IIb trial for Pruritus (In children, In adolescents, In adults) in USA (Topical) (NCT03322137)
  • 12 Feb 2018 Phase-II clinical trials in Plaque psoriasis in Canada (Topical) (NCT03448081)
  • 12 Feb 2018 Phase-II clinical trials in Pruritus in Canada (Topical) (NCT03448081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top